# Avego Bioscience Capital

> Avego Bioscience Capital is a VC fund backing Biotechnology and Therapeutics. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 7
- Last investment: Jun 2026
- Lead investor: 14%
- Last updated: Aug 2026

Avego Bioscience Capital is an investment firm.

## Contacts

5 contacts available for Avego Bioscience Capital. Shizune tracks 1 team members at Avego Bioscience Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/avego-bioscience-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 43% |
| Therapeutics | 2 | 29% |
| Medical | 1 | 14% |
| Biopharma | 1 | 14% |
| Health Care | 1 | 14% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 14% |
| Series C | 1 | 14% |
| Series D | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 29% |
| United Kingdom | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Eric Pham | Managing Director | 5 | https://shizune.co/investors/profile/eric-pham-8e51 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Memento Medicines | Memento Medicines is a biotechnology company focused on the development of novel antibody therapies for ophthalmology. The company's core business model centers on licensing and advancing specialized, multi-target biologics to address high-demand clinical needs in the retinal disease landscape. Its primary value proposition rests on its leadprogram, MMT-205, a dual-action bispecific antibody engineered to simultaneously activate Tie2 receptors and inhibit VEGF. This therapeutic candidate is being clinical developed to improve treatment durability and visual outcomes for individuals suffering from neovascular age-related macular degeneration and diabetic macular edema. | $93M | Series A | Jun 18, 2026 |  |
| CellCentric | CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer. | $220M | Series D | May 06, 2026 |  |
| TRex Bio | TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. | $50M |  | Jan 27, 2026 |  |
| EpiBiologics | EpiBiologics develops first-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology. | $107M | Series B | Jan 08, 2026 |  |
| MapLight Therapeutics | MapLight Therapeutics offers a platform designed to discover and develop therapeutics for brain disorders. It combines single-cell transcriptomics and optogenetics to identify novel drug targets and develop effective therapies for brain disorders. | $372.5M | Series D | Jul 28, 2025 |  |
| TRex Bio | TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. | $84M | Series B | Nov 13, 2024 |  |
| Ribon Therapeutics | Ribon Therapeutics is a biotechnology company pioneering the discovery of new cancer medicines that target monoPARP proteins, critical regulators of cancer survival mechanisms.The diverse and central functions that PARPs, or poly(ADP-ribose) polymerases, play in cancer cell survival pathways are just emerging, and many of the seminal discoveriesin the field have been made by Ribon’s scientific founders. By combining insights from our founders and an experienced management team, Ribon is building a proprietary drug discovery platform to investigate the molecular action and biological function of a subset of the PARP protein family, called monoPARPs. Based on its platform, Ribon is creating a pipeline of innovative medicines that selectively target monoPARPs to treat cancer and may have the potential to impact other diseases. The company is backed by prominent life science investors, including The Column Group, U.S. Venture Partners, Deerfield Management and Osage University Partners. | $65M | Series C | Jun 14, 2021 |  |

7 of 7 investments shown.

## Co-investors
- [Johnson & Johnson Innovation](https://shizune.co/investors/profile/johnson-johnson-innovation-jjdc) — VC Fund, 4 deals together
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 3 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 3 deals together
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 3 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 2 deals together
- [Delos Capital](https://shizune.co/investors/profile/delos-capital-%E5%BA%B7%E7%A6%A7%E5%85%A8%E7%90%83%E6%8A%95%E8%B3%87%E5%9F%BA%E9%87%91) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Avego Bioscience Capital invest in?

Avego Bioscience Capital invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Series B and Series C stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Avego Bioscience Capital?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Avego Bioscience Capital?

The team at Avego Bioscience Capital includes Eric Pham (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co